Year: 2011 Volume: 48 Supplement : 2
Editorial
Editorial
Other
Past and Present of Disease-Modifying Treatments in Multiple Sclerosis
Mefkure Eraksoy
Natalizumab Treatment in Multiple Sclerosis
Murat Kürtüncü
Review on PML Risk Stratification in Natalizumab-Treated Multiple Sclerosis Patients
Nikolaos C. GRIGORIADIS
The First FDA-Approved Oral Drug for Multiple Sclerosis: Fingolimod
Gülşen Akman Demir
New Oral Treatments Expected to be Available for Multiple Sclerosis
Aslı KIYAT ATAMER
The Role of B Cells in Multiple Sclerosis Pathogenesis and Monoclonal Antibody Treatments Targeting B Cells
Erdem Tüzün
Multipl Sklerozda Alemtuzumab
Laura AZZOPARDI,
Alasdair COLES
Symptomatic Menagement in Multiple Sclerosis
Serkan ÖZAKBAŞ
2012 © Galenos Yayınevi | All Rights Reserved. Privacy Statement | Access 